<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493151</url>
  </required_header>
  <id_info>
    <org_study_id>59752</org_study_id>
    <nct_id>NCT04493151</nct_id>
  </id_info>
  <brief_title>Imipenem/Cilastatin/Relebactam PK in ECMO</brief_title>
  <official_title>Pharmacokinetics of Imipenem/Cilastatin/Relebactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph L. Kuti, PharmD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for&#xD;
      critically ill patients where blood is extracted from the vascular system and circulated by a&#xD;
      mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is&#xD;
      well known that critically ill patients may experience alterations in antibiotic&#xD;
      pharmacokinetics, and as a result, dosing modifications are generally required. There is a&#xD;
      need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs.&#xD;
      This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic,&#xD;
      imipenem-cilastatin-relebactam, in critically ill patients receiving ECMO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label study to determine imipenem-cilastatin-relebactam&#xD;
      pharmacokinetics in critically ill patients receiving ECMO. Eight patients with suspected&#xD;
      suspected sepsis and who are receiving ECMO will be enrolled. Each participant will receive&#xD;
      four to six doses of imipenem-cilastatin-relebactam according to current approved prescribing&#xD;
      information, followed by ten blood samples to determine concentrations. Non-compartmental and&#xD;
      population pharmacokinetic analyses will be determined to assess the effects of ECMO on&#xD;
      imipenem and relebactam pharmacokinetic parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Imipenem Clearance</measure>
    <time_frame>6 hours</time_frame>
    <description>The clearance in liters/hour of imipenem from the plasma of critically ill patients receiving ECMO.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relebactam Clearance</measure>
    <time_frame>6 hours</time_frame>
    <description>The clearance in liters/hour of relebactam from the plasma of critically ill patients receiving ECMO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imipenem Area Under the Curve (AUC)</measure>
    <time_frame>6 hours</time_frame>
    <description>The AUC in milligram*hour/liter of imipenem calculated from concentrations collected between zero and 6 hours at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relebactam Area Under the Curve (AUC)</measure>
    <time_frame>6 hours</time_frame>
    <description>The AUC in milligram*hour/liter of relebactam calculated from concentrations collected between zero and 6 hours at steady-state</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Imipenem-Cilastatin-Relebactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem, Cilastatin and Relebactam</intervention_name>
    <description>After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.</description>
    <arm_group_label>Imipenem-Cilastatin-Relebactam</arm_group_label>
    <other_name>Recarbrio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older;&#xD;
&#xD;
          -  On support with Veno-venous- or Veno-arterial-ECMO;&#xD;
&#xD;
          -  Documented infection or presumed infection as confirmed by the presence of at least&#xD;
             one of the following criteria within the past 72 hours:&#xD;
&#xD;
               -  Documented fever (oral, rectal, tympanic, or core temperature &gt; 38.5° C)&#xD;
&#xD;
               -  Hypothermia (oral, rectal, tympanic, or core temperature &lt; 35.0° C)&#xD;
&#xD;
               -  An elevated white blood cell (WBC) count ≥ 12,000 cells/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If female, currently pregnant or breast feeding;&#xD;
&#xD;
          -  History of any moderate or severe hypersensitivity or allergic reaction to any&#xD;
             β-lactam agent (a history of mild rash to a β-lactam followed by uneventful&#xD;
             re-exposure is not a contraindication);&#xD;
&#xD;
          -  Severe renal dysfunction defined as a creatinine clearance &lt; 15 mL/min (calculated by&#xD;
             the Cockcroft-Gault equation using actual body weight) or requirement for continuous&#xD;
             renal replacement therapy or hemodialysis;&#xD;
&#xD;
          -  Hemoglobin less than 8 mg/dL at baseline;&#xD;
&#xD;
          -  Use of probenecid, valproic acid, or imipenem within 3 days before study drug&#xD;
             infusion;&#xD;
&#xD;
          -  Acute liver injury, defined as aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt; 5 times the upper limit of normal, or AST or ALT &gt; 3 times&#xD;
             the upper limit of normal with an associated total bilirubin &gt; 2 times upper limit of&#xD;
             normal;&#xD;
&#xD;
          -  Any rapidly-progressing disease or immediately life-threatening illness (defined as&#xD;
             imminent death within 48 hours in the opinion of the investigator);&#xD;
&#xD;
          -  Any condition or circumstance that, in the opinion of the investigator, would&#xD;
             compromise the safety of the patient or the quality of study data;&#xD;
&#xD;
          -  Planned or prior participation in any other interventional drug study within 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Kuti, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph L Kuti, PharmD</last_name>
    <phone>8609723612</phone>
    <email>joseph.kuti@hhchealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Martin</last_name>
    <phone>8609729290</phone>
    <email>elizabeth.martin@hhchealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph L Kuti, PharmD</last_name>
      <phone>860-972-3612</phone>
      <email>joseph.kuti@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>David P Nicolau, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomefa Asempa, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Gluck, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Joseph L. Kuti, PharmD</investigator_full_name>
    <investigator_title>Associate Director, Center for Anti-Infective Research and Development</investigator_title>
  </responsible_party>
  <keyword>beta-lactam</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Relebactam</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

